What Does 2025 Hold For Pharma?

By Darcy Grabenstein

In 2025, the pharmaceutical industry is expected to undergo transformative changes influenced by advancements in technology and evolving regulatory landscapes. A significant trend will be the integration of Artificial Intelligence (AI) in drug discovery and personalized medicine, with a focus on establishing regulatory frameworks to mitigate associated risks. The FDA's anticipated guidance on enhancing diversity in clinical trials will mandate sponsors to set specific demographic goals, promoting inclusivity for underrepresented groups. Additionally, Europe is expected to lead in clinical trial transparency, with new regulations shaping disclosure practices.

Citeline's Thomas Wicks predicts a rise in demand for plain language summaries and improved data anonymization for GDPR compliance. Meanwhile, the APAC region will witness a surge in drug innovation, particularly in China, alongside evolving regulatory environments in Japan and India. The weight-loss drug market, especially for GLP-1 drugs, is projected to grow, while decentralized clinical trials will gain traction, driven by AI and patient-centric strategies. Lastly, emerging research linking COVID-19 to potential cancer treatment strategies may further influence industry directions, necessitating adaptability in this dynamic landscape.